Symbiotec Pharmalab Files DRHP with SEBI for ₹2,180 Crore IPO
Mumbai: Symbiotec Pharmalab Limited, a research-driven pharmaceutical and biotechnology company, has filed its Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (SEBI) to raise up to ₹2,180 crore through an initial public offering (IPO).
The proposed IPO comprises a fresh issue of equity shares worth ₹150 crore and an offer for sale (OFS) by selling shareholders aggregating up to ₹2,030 crore. The equity shares, with a face value of ₹2 each, are proposed to be listed on both the BSE and the National Stock Exchange (NSE).
Fund Utilisation
The company intends to use the net proceeds from the fresh issue for:
- Prepayment and/or repayment of certain outstanding borrowings.
- General corporate purposes.
Industry Leadership
Symbiotec Pharmalab holds a global leadership position in corticosteroid and steroidal-hormone APIs, with a 36.2% global market share in corticosteroids and 44.2% in steroidal-hormone APIs in Fiscal 2025 (Source: F&S Report). It is the only Indian and global company with a presence across the top 10 corticosteroid and steroidal-hormone APIs, underscoring the depth of its portfolio.
The company manufactures these products using fermentation and multi-step complex chemical reactions. With over 30 years of industry experience, Symbiotec has grown from a lab-scale steroidal-hormone API manufacturer in 1995 into an industrial-scale, backward-integrated platform. Its facilities hold approvals from the US FDA, EU-GMP, Ministry of Food and Drug Safety, Korea, and other global regulatory bodies.
Lead Managers
The IPO is being managed by JM Financial Limited, Avendus Capital Private Limited, Motilal Oswal Investment Advisors Limited, and Nomura Financial Advisory and Securities (India) Private Limited as the Book Running Lead Managers.
